1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Pseudoxanthoma Elasticum - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Pseudoxanthoma Elasticum - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Pseudoxanthoma Elasticum - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age 2018-2034
7.2.4 Epidemiology by Gender 2018-2034
7.2.5 Diagnosed Cases 2018-2034
7.2.6 Patient Pool/Treated Cases 2018-2034
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age 2018-2034
7.3.4 Epidemiology by Gender 2018-2034
7.3.5 Diagnosed Cases 2018-2034
7.3.6 Patient Pool/Treated Cases 2018-2034
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age 2018-2034
7.4.4 Epidemiology by Gender 2018-2034
7.4.5 Diagnosed Cases 2018-2034
7.4.6 Patient Pool/Treated Cases 2018-2034
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age 2018-2034
7.5.4 Epidemiology by Gender 2018-2034
7.5.5 Diagnosed Cases 2018-2034
7.5.6 Patient Pool/Treated Cases 2018-2034
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age 2018-2034
7.6.4 Epidemiology by Gender 2018-2034
7.6.5 Diagnosed Cases 2018-2034
7.6.6 Patient Pool/Treated Cases 2018-2034
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age 2018-2034
7.7.4 Epidemiology by Gender 2018-2034
7.7.5 Diagnosed Cases 2018-2034
7.7.6 Patient Pool/Treated Cases 2018-2034
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age 2018-2034
7.8.4 Epidemiology by Gender 2018-2034
7.8.5 Diagnosed Cases 2018-2034
7.8.6 Patient Pool/Treated Cases 2018-2034
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age 2018-2034
7.9.4 Epidemiology by Gender 2018-2034
7.9.5 Diagnosed Cases 2018-2034
7.9.6 Patient Pool/Treated Cases 2018-2034
8 Pseudoxanthoma Elasticum - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Pseudoxanthoma Elasticum - Unmet Needs
10 Pseudoxanthoma Elasticum - Key Endpoints of Treatment
11 Pseudoxanthoma Elasticum - Marketed Products
11.1 List of Pseudoxanthoma Elasticum Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Pseudoxanthoma Elasticum - Pipeline Drugs
12.1 List of Pseudoxanthoma Elasticum Pipeline Drugs Across the Top 7 Markets
12.1.1 DS-1211b - Daiichi Sankyo
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Pseudoxanthoma Elasticum - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Pseudoxanthoma Elasticum – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Pseudoxanthoma Elasticum - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pseudoxanthoma Elasticum - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pseudoxanthoma Elasticum - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pseudoxanthoma Elasticum - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pseudoxanthoma Elasticum - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pseudoxanthoma Elasticum - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pseudoxanthoma Elasticum - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pseudoxanthoma Elasticum - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pseudoxanthoma Elasticum - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pseudoxanthoma Elasticum - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pseudoxanthoma Elasticum - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pseudoxanthoma Elasticum - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pseudoxanthoma Elasticum - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pseudoxanthoma Elasticum - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pseudoxanthoma Elasticum - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pseudoxanthoma Elasticum - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pseudoxanthoma Elasticum - Access and Reimbursement Overview
16 Pseudoxanthoma Elasticum - Recent Events and Inputs From Key Opinion Leaders
17 Pseudoxanthoma Elasticum Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Pseudoxanthoma Elasticum Market – Strategic Recommendations
19 Appendix